A Chlamydia Trachomatis VD1-MOMP Vaccine Elicits Cross-neutralizing and Protective Antibodies Against C/C-related Complex Serovars

Overview

Journal NPJ Vaccines

Date 2021 Apr 20

PMID 33875654

Citations 12

Authors

Anja Weinreich Olsen

Ida Rosenkrands

Martin J Holland

Peter Andersen

Frank Follmann

Affiliations

Soon will be listed here.

Abstract

Ocular and urogenital infections with Chlamydia trachomatis (C.t.) are caused by a range of different serovars. The first C.t. vaccine in clinical development (CTH522/CAF®01) induced neutralizing antibodies directed to the variable domain 4 (VD4) region of major outer membrane protein (MOMP), covering predominantly B and intermediate groups of serovars. The VD1 region of MOMP contains neutralizing B-cell epitopes targeting serovars of the C and C-related complex. Using an immuno-repeat strategy, we extended the VD1 region of SvA and SvJ to include surrounding conserved segments, extVD1 and extVD1, and repeated this region four times. The extVD1*4 was most immunogenic with broad cross-surface and neutralizing reactivity against representative members of the C and C-related complex serovars. Importantly, in vitro results for extVD1*4 translated into in vivo biological effects, demonstrated by in vivo neutralization of SvA and protection/cross-protection against intravaginal challenge with both SvA and the heterologous SvIa strain.

Citing Articles

Viral Vector-Based Vaccines Encoding CTH522 Induce Distinct Immune Responses in C57BL/6J and HLA Transgenic Mice.

Andreacchio G, Longo Y, Moreno Mascaraque S, Anandasothy K, Tofan S, Ozun E Vaccines (Basel). 2024; 12(8).

PMID: 39204067 PMC: 11360449. DOI: 10.3390/vaccines12080944.

Advances in Vaccination: Unveiling the Potential of Major Outer Membrane Protein Derivative Constructs.

Kiekens C, Morre S, Vanrompay D Microorganisms. 2024; 12(6).

PMID: 38930578 PMC: 11205628. DOI: 10.3390/microorganisms12061196.

Effects of prime-boost strategies on the protective efficacy and immunogenicity of a PLGA (85:15)-encapsulated Chlamydia recombinant MOMP nanovaccine.

Sahu R, Verma R, Egbo T, Giambartolomei G, Singh S, Dennis V Pathog Dis. 2024; 82.

PMID: 38862192 PMC: 11186516. DOI: 10.1093/femspd/ftae004.

Immune signature of Chlamydia vaccine CTH522/CAF®01 translates from mouse-to-human and induces durable protection in mice.

Olsen A, Rosenkrands I, Jacobsen C, Cheeseman H, Kristiansen M, Dietrich J Nat Commun. 2024; 15(1):1665.

PMID: 38396019 PMC: 10891140. DOI: 10.1038/s41467-024-45526-2.

Enhancement of Macrophage Immunity against Chlamydial Infection by Natural Killer T Cells.

Peng Y, Qiao S, Wang H, Shekhar S, Wang S, Yang J Cells. 2024; 13(2).

PMID: 38247825 PMC: 10813948. DOI: 10.3390/cells13020133.

References

Taylor H, Burton M, Haddad D, West S, Wright H . Trachoma. Lancet. 2014; 384(9960):2142-52. DOI: 10.1016/S0140-6736(13)62182-0. View

Abdelsamed H, Peters J, Byrne G . Genetic variation in Chlamydia trachomatis and their hosts: impact on disease severity and tissue tropism. Future Microbiol. 2013; 8(9):1129-1146. PMC: 4009991. DOI: 10.2217/fmb.13.80. View

Olsen A, Follmann F, Erneholm K, Rosenkrands I, Andersen P . Protection Against Chlamydia trachomatis Infection and Upper Genital Tract Pathological Changes by Vaccine-Promoted Neutralizing Antibodies Directed to the VD4 of the Major Outer Membrane Protein. J Infect Dis. 2015; 212(6):978-89. DOI: 10.1093/infdis/jiv137. View

Dawson C, JAWETZ E, Hanna L, Rose L, Wood T, THYGESON P . Experimental inclusion conjunctivitis in man. II. Partial resistance to reinfection. Am J Epidemiol. 1966; 84(3):411-25. DOI: 10.1093/oxfordjournals.aje.a120654. View

GRAYSTON J, Wang S, Yang Y, WOOLRIDGE R . The effect of trachoma virus vaccine on the course of experimental trachoma infection in blind human volunteers. J Exp Med. 1962; 115:1009-22. PMC: 2137531. DOI: 10.1084/jem.115.5.1009. View

JAWETZ E, Rose L, Hanna L, THYGESON P . Experimental inclusion conjunctivitis in man: measurements of infectivity and resistance. JAMA. 1965; 194(6):620-32. View

Barenfanger J, MacDONALD A . The role of immunoglobulin in the neutralization of trachoma infectivity. J Immunol. 1974; 113(5):1607-17. View

Wang S, GRAYSTON J . Micro-immunofluorescence antibody responses to trachoma vaccines. Int Ophthalmol. 1988; 12(1):73-80. DOI: 10.1007/BF00133785. View

Bush R, Peterson E, Schirmer T, de la Maza L . Prediction of the membrane-spanning beta-strands of the major outer membrane protein of Chlamydia. Protein Sci. 2002; 11(7):1854-61. PMC: 2373662. DOI: 10.1110/ps.3650102. View

10.

Wang S, Kuo C, BARNES R, Stephens R, GRAYSTON J . Immunotyping of Chlamydia trachomatis with monoclonal antibodies. J Infect Dis. 1985; 152(4):791-800. DOI: 10.1093/infdis/152.4.791. View

11.

Yuan Y, Zhang Y, Watkins N, Caldwell H . Nucleotide and deduced amino acid sequences for the four variable domains of the major outer membrane proteins of the 15 Chlamydia trachomatis serovars. Infect Immun. 1989; 57(4):1040-9. PMC: 313226. DOI: 10.1128/iai.57.4.1040-1049.1989. View

12.

Peterson E, Cheng X, Markoff B, Fielder T, de la Maza L . Functional and structural mapping of Chlamydia trachomatis species-specific major outer membrane protein epitopes by use of neutralizing monoclonal antibodies. Infect Immun. 1991; 59(11):4147-53. PMC: 259009. DOI: 10.1128/iai.59.11.4147-4153.1991. View

13.

Caldwell H, Kromhout J, Schachter J . Purification and partial characterization of the major outer membrane protein of Chlamydia trachomatis. Infect Immun. 1981; 31(3):1161-76. PMC: 351439. DOI: 10.1128/iai.31.3.1161-1176.1981. View

14.

Pal S, Theodor I, Peterson E, de la Maza L . Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect Immun. 2001; 69(10):6240-7. PMC: 98757. DOI: 10.1128/IAI.69.10.6240-6247.2001. View

15.

Pal S, Luke C, Barbour A, Peterson E, de la Maza L . Immunization with the Chlamydia trachomatis major outer membrane protein, using the outer surface protein A of Borrelia burgdorferi as an adjuvant, can induce protection against a chlamydial genital challenge. Vaccine. 2003; 21(13-14):1455-65. DOI: 10.1016/s0264-410x(02)00680-1. View

16.

Pal S, Peterson E, de la Maza L . Vaccination with the Chlamydia trachomatis major outer membrane protein can elicit an immune response as protective as that resulting from inoculation with live bacteria. Infect Immun. 2005; 73(12):8153-60. PMC: 1307068. DOI: 10.1128/IAI.73.12.8153-8160.2005. View

17.

Pal S, Peterson E, Rappuoli R, Ratti G, de la Maza L . Immunization with the Chlamydia trachomatis major outer membrane protein, using adjuvants developed for human vaccines, can induce partial protection in a mouse model against a genital challenge. Vaccine. 2005; 24(6):766-75. DOI: 10.1016/j.vaccine.2005.08.074. View

18.

Sun G, Pal S, Weiland J, Peterson E, de la Maza L . Protection against an intranasal challenge by vaccines formulated with native and recombinant preparations of the Chlamydia trachomatis major outer membrane protein. Vaccine. 2009; 27(36):5020-5. PMC: 2741729. DOI: 10.1016/j.vaccine.2009.05.008. View

19.

Hansen J, Jensen K, Follmann F, Agger E, Theisen M, Andersen P . Liposome delivery of Chlamydia muridarum major outer membrane protein primes a Th1 response that protects against genital chlamydial infection in a mouse model. J Infect Dis. 2008; 198(5):758-67. DOI: 10.1086/590670. View

20.

Tifrea D, Ralli-Jain P, Pal S, de la Maza L . Vaccination with the recombinant major outer membrane protein elicits antibodies to the constant domains and induces cross-serovar protection against intranasal challenge with Chlamydia trachomatis. Infect Immun. 2013; 81(5):1741-50. PMC: 3648024. DOI: 10.1128/IAI.00734-12. View